Briacell Total Cash From Operating Activities from 2010 to 2026
| BCT Stock | 5.88 0.02 0.34% |
Total Cash From Operating Activities | First Reported 2006-10-31 | Previous Quarter -8.1 M | Current Value -10.7 M | Quarterly Volatility 2.7 M |
Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 45.6 M, Total Operating Expenses of 45.4 M or Depreciation And Amortization of 178.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.19. Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.
Briacell | Total Cash From Operating Activities |
Evaluating Briacell Therapeutics's Total Cash From Operating Activities across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Briacell Therapeutics Corp's fundamental strength.
Latest Briacell Therapeutics' Total Cash From Operating Activities Growth Pattern
Below is the plot of the Total Cash From Operating Activities of Briacell Therapeutics Corp over the last few years. It is Briacell Therapeutics' Total Cash From Operating Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Briacell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Cash From Operating Activities | 10 Years Trend |
|
Total Cash From Operating Activities |
| Timeline |
Briacell Total Cash From Operating Activities Regression Statistics
| Arithmetic Mean | (9,377,871) | |
| Coefficient Of Variation | (116.79) | |
| Mean Deviation | 9,611,520 | |
| Median | (3,805,725) | |
| Standard Deviation | 10,952,032 | |
| Sample Variance | 119.9T | |
| Range | 28.1M | |
| R-Value | (0.89) | |
| Mean Square Error | 26.7T | |
| R-Squared | 0.79 | |
| Slope | (1,929,616) | |
| Total Sum of Squares | 1919.2T |
Briacell Total Cash From Operating Activities History
About Briacell Therapeutics Financial Statements
Briacell Therapeutics investors utilize fundamental indicators, such as Total Cash From Operating Activities, to predict how Briacell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Cash From Operating Activities | -25.4 M | -24.1 M |
Pair Trading with Briacell Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Briacell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Briacell Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Briacell Stock
Moving against Briacell Stock
| 0.85 | CFW | Calfrac Well Services | PairCorr |
| 0.79 | LA | Los Andes Copper | PairCorr |
| 0.78 | SMD | Strategic Metals | PairCorr |
| 0.78 | ECU | Element 29 Resources | PairCorr |
| 0.77 | TTE | TotalEnergies CDR | PairCorr |
The ability to find closely correlated positions to Briacell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Briacell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Briacell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Briacell Therapeutics Corp to buy it.
The correlation of Briacell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Briacell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Briacell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Briacell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Briacell Therapeutics Correlation against competitors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.